ContractParticipating Site Agreement • September 10th, 2012
PARTICIPATING SITE AGREEMENT ZMLUVA O ÚČASTI KLINICKÉHO PRACOVISKA NA ŠTÚDII This Participating Site Agreement (this “Agreement”) is entered into on 27.06.2012 (“Effective Date”), Táto Zmluva o účasti klinického pracoviska na štúdii (ďalej ako “Zmluva”) sa uzatvára dňa 27.06.2012 (“Deň účinnosti”), by and between medzi Outcome Europe Sàrl, with and address at chemin du Glapin 6, 1162 St-Prex, Switzerland (hereinafter referred to as “Company”), Outcome Europe Sàrl so sídlom na chemin du Glapin 6, 1162 St-Prex, Švajčiarsko (ďalej ako „Spoločnosť“), and a FNsP F.D.Roosevelta, with address at Nám.L.Svobodu 1, 975 17 Banská Bystrica, Slovakia (hereinafter referred to as “Clinician Site”), FNsP F.D.Roosevelta, so sídlom na Nám.L.Svobodu 1, 975 17 Banská Bystrica, Slovakia (ďalej ako “Klinické pracovisko”), a and Dr. Mária Molnárová, with the address at FNsP F.D.Roosevelta, Nám. L.Svobodu 1, 975 17 Banská Bystrica, Slovakia (hereinafter referred to as “Investigator”), Dr. Mária Molnárová,
ContractParticipating Site Agreement • May 5th, 2020
PARTICIPATING SITE AGREEMENT SMLOUVA O ÚČASTI PRACOVIŠTĚ This Participating Site Agreement (this “Agreement”) is entered into by parties by and among Glaxo Group Limited, 980 Great West Road, Brentford, ,Middlesex, TW8 9GS UK (“Sponsor”), Quintiles Czech Republic, s.r.o., having a place of business at Praha 5, Jinonice, Radlická 714/113a, zip code 158 00 Prague, Czech Republic, Identification number: CZ247 68 651, represented by (“Company”), Hospital Bulovka, (“Clinician Site”), with an address at Budinova 67/2, 180 81 Prague 8, Czech Republic, represented by Dr Tomáš Podlešák, Director of Preventative Care, on the basis of a corporate power of attorney, and is effective asof the date of last signature hereto (“Effective Date”). Tato smlouva o účasti pracoviště (dále jen„smlouva“) je uzavřena mezi stranami, a to společností Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS UK („zadavatel“), společností Quintiles Czech Republic, s.r.o. se sídlem v Praze 5, Jino
PARTICIPATING SITE AGREEMENT SMLOUVA S MÍSTEM PROVÁDĚNÍParticipating Site Agreement • December 16th, 2020
ContractParticipating Site Agreement • March 24th, 2017
PARTICIPATING SITE AGREEMENT SMLOUVA O ÚČASTI PRACOVIŠTĚ This Participating Site Agreement (this “Agreement”) is entered into the date of last signature by parties (the “Effective Date”), by and among Glaxo Group Limited, 980 Great West Road, Brentford, ,Middlesex, TW8 9GS UK ( “Sponsor”), Quintiles Czech Republic, s.r.o., having a place of business at Praha 5, Jinonice, Radlická 714/113a, zip code 158 00 Prague, Czech Republic, Identification number: CZ247 68 651, ( “Company”), Nemocnice Jihlava ( “Clinician Site), with an address at Vrchlického 59, 586 33 Jihlava, Czech Republic and MUDr., having a place of business at, ČR ( “Principal Investigator”). Clinician Site and Principal Investigator are hereinafter referred to collectively as “Site.”) Tato smlouva o účasti pracoviště (dále jen„smlouva“) je uzavřena ke dni podpisu poslední ze stran (dále jen „datum účinnosti“), a to společností Glaxo Group Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS UK (dále jen „zadavate
ContractParticipating Site Agreement • November 20th, 2019
PARTICIPATING SITE AGREEMENT SMLOUVA SE ZÚČASTNĚNÝM PRACOVIŠTĚM This Participating Site Agreement (“Agreement”) is by and between Fresenius Kabi Deutschland GmbH, which has a place of business at Else-Kröner-Straße 1, 61352 Bad Homburg, Germany (“Sponsor”), IQVIA Commercial GmbH & Co. OHG, having a place of business at Main Airport Center, Unterschweinstiege 2-14, 60549 Frankfurt am Main, Germany (“Company”), Fakultní nemocnicí Plzeň, located at Edvarda Beneše 1128/13, 305 99 Plzeň, Czech Republic (“Site”). Tato Smlouva se zúčastněným pracovištěm („Smlouva“) je uzavřena mezi společností Fresenius Kabi Deutschland GmbH se sídlem na adrese Else-Kröner-Straße 1, 61352 Bad Homburg, Německo („Zadavatel“), IQVIA Commercial GmbH & Co. OHG se sídlem na adrese Main Airport Center, Unterschweinstiege 2-14, 60549 Frankfurt am Main, Německo („Společnost“), Fakultní nemocnicí Plzeň, na adrese Edvarda Beneše 1128/13, 305 99 Plzeň, Česká republika („Pracoviště“). 1. Conduct of the Study. Company
ContractParticipating Site Agreement • April 18th, 2022
PARTICIPATING SITE AGREEMENT SMLOUVA O ÚČASTI CENTRA KLINICKÉHO HODNOCENÍ This Participating Site Agreement (“Agreement”) is by and between IQVIA RDS AG, Branch St- Prex, located at Route de Pallatex 29, 1162 St- Prex, Switzerland with a tax number CHE- 106.402.567, acting through its Legal representative , in hercapacity as a Director of Clinical Operations or when applicable in her capacity as a Project Manager (“Company”) and Tato smlouva o účasti Centra klinického hodnocení (dále jen „Smlouva“) je uzavírána mezi následujícími stranami: IQVIA RDS AG, Branch St-Prex, se sídlem Route de Pallatex 29, 1162 St-Prex, Švýcarsko, DIČ: CHE-106.402.567jednající prostřednictvím jejího právního zástupce paní ve své funkci ředitelky klinického provozu, případně ve své funkci projektového manažera („ Společnost “) a Motol University Hospital, state contributory organization (hereinafter referred to as “Healthcare Provider" or "Provider"), with an address at V Úvalu 84, 150 06 Praha 5, Czech Repub
ContractParticipating Site Agreement • April 2nd, 2014
AMENDMENT 1to the PARTICIPATING SITE AGREEMENT A Prospective Observational Study with protocol entitled: “LUMINOUS: Study to observe the effectiveness and safety of LUCENTIS® through individualized patient treatment and associated outcomes” Hereinafter: “the Study” BetweenFNsP F.D.Roosevelta, with address at Nám. L.Svobodu 1, 975 17 Banská Bystrica, Slovakia (hereinafter referred to as “Clinician Site”), AndDr. Mária Molnárová, with the address at FNsP F.D.Roosevelta, Nám. L.Svobodu 1, 975 17 Banská Bystrica, Slovakia(hereinafter referred to as “Investigator”), AndOutcome Europe SàrlCh. Du Glapin 61162, St.-Prex, Switzerland Hereinafter: “Company”(the parties hereinafter referred to as individually the “party” and jointly as the “parties”). WHEREAS, on June 27, 2012, the parties entered into the Participating Site Agreement for a Prospective Observational Study entitled Luminous for the conduct of the Study (the “Agreement”);¨ WHEREAS, Dr. Mária Molnárová has been designated as the pri
National Survey of College Internships Participating Site Agreement: Fall 2022 AdministrationParticipating Site Agreement • April 15th, 2022
The National Survey of College Internships Participating Site Agreement (“Agreement”) are the terms under which the Board of Regents of the University of Wisconsin System, on behalf of the University of Wisconsin-Madison (“UW” we or our) provide the National Survey for College Internships (“NSCI”or NSCI Study) to participating Institutions (“SITE” you or your). When you register for the NSCI, you are accepting the terms of this Agreement and representing that you have authority to accept such terms on behalf of your institution.
OWN THE BONE® PARTICIPATING SITE AGREEMENTParticipating Site Agreement • December 28th, 2020 • Illinois
This Participating Site Agreement (“Agreement”) is, by and between the American Orthopaedic Association, an Illinois Not-for-Profit Corporation with its principal place of business at 9400 W. Higgins Road, #205, Rosemont, Illinois 60018 (“AOA”) and [Institution Name] , with its principal place of business at [Institution Address]. This Agreement is effective on the date last executed below (“Effective Date”).
